- Home
- NIVF vs SBFM Comparison
NIVF vs SBFM Comparison
Compare NIVF & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- SBFM
- Stock Information
- Founded
- NIVF 2011
- SBFM 2006
- Country
- NIVF Thailand
- SBFM United States
- Employees
- NIVF N/A
- SBFM N/A
- Industry
- NIVF
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- SBFM Health Care
- Exchange
- NIVF NYSE
- SBFM Nasdaq
- Market Cap
- NIVF 12.2M
- SBFM 3.7M
- IPO Year
- NIVF N/A
- SBFM N/A
- Fundamental
- Price
- NIVF $1.16
- SBFM $3.14
- Analyst Decision
- NIVF
- SBFM
- Analyst Count
- NIVF 0
- SBFM 0
- Target Price
- NIVF N/A
- SBFM N/A
- AVG Volume (30 Days)
- NIVF 11.9M
- SBFM 90.8K
- Earning Date
- NIVF 11-16-2024
- SBFM 11-11-2024
- Dividend Yield
- NIVF N/A
- SBFM N/A
- EPS Growth
- NIVF N/A
- SBFM N/A
- EPS
- NIVF 0.21
- SBFM N/A
- Revenue
- NIVF $5,136,153.00
- SBFM $30,481,982.00
- Revenue This Year
- NIVF N/A
- SBFM $86.70
- Revenue Next Year
- NIVF N/A
- SBFM $126.76
- P/E Ratio
- NIVF $5.39
- SBFM N/A
- Revenue Growth
- NIVF N/A
- SBFM 109.82
- 52 Week Low
- NIVF $0.55
- SBFM $2.42
- 52 Week High
- NIVF $17.24
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- SBFM 52.62
- Support Level
- NIVF $1.07
- SBFM $2.85
- Resistance Level
- NIVF $3.28
- SBFM $3.05
- Average True Range (ATR)
- NIVF 0.42
- SBFM 0.14
- MACD
- NIVF 0.05
- SBFM 0.03
- Stochastic Oscillator
- NIVF 22.42
- SBFM 85.29
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.